The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Resveratrol Promotes Clearance of Alzheimer's Disease Amyloid-β Peptides
Open accessAbstract
Several epidemiological studies indicate that moderate consumption of wine is associated with a lower incidence of Alzheimer's disease. Wine is enriched in antioxidant compounds with potential neuroprotective activities. However, the exact molecular mechanisms involved in the beneficial effects of wine intake on the neurodegenerative process in Alzheimer's disease brain remain to be clearly defined. Here we show that resveratrol (trans-3,4',5-trihydroxystilbene), a naturally occurring polyphenol mainly found in grapes and red wine, markedly lowers the levels of secreted and intracellular amyloid-beta (Abeta) peptides produced from different cell lines. Resveratrol does not inhibit Abeta production, because it has no effect on the Abeta-producing enzymes beta- and gamma-secretases, but promotes instead intracellular degradation of Abeta via a mechanism that involves the proteasome. Indeed, the resveratrol-induced decrease of Abeta could be prevented by several selective proteasome inhibitors and by siRNA-directed silencing of the proteasome subunit beta5. These findings demonstrate a proteasome-dependent anti-amyloidogenic activity of resveratrol and suggest that this natural compound has a therapeutic potential in Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
β-catenin is a target for the ubiquitin–proteasome pathway
Aberle, H., Bauer, A., Stappert, J., Kispert, A., & Kemler, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3797 · Cited by 2,529
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060
Impaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848
Marambaud, P. (2002) · The EMBO Journal · doi:10.1093/emboj/21.8.1948 · Cited by 685
Self-citationResveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons
Parker, J. A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H., & Néri, C. (2005) · Nature Genetics · doi:10.1038/ng1534 · Cited by 512
Marambaud, P., Wen, P. H., Dutt, A., Shioi, J., Takashima, A., Siman, R., & Robakis, N. K. (2003) · Cell · doi:10.1016/j.cell.2003.08.008 · Cited by 464
Self-citation
Cited by
Plant Polyphenols: Chemical Properties, Biological Activities, and Synthesis
Quideau, S., Deffieux, D., Douat‐Casassus, C., & Pouységu, L. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201000044 · Cited by 2,730
Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
Role of Phenolic Compounds in Human Disease: Current Knowledge and Future Prospects
Rahman, M. M., Rahaman, M. S., Islam, M. R., Rahman, F., Mithi, F. M., Alqahtani, T., Almikhlafi, M. A., Alghamdi, S. Q., Alruwaili, A. S., Hossain, M. S., et al. (2021) · Molecules · doi:10.3390/molecules27010233 · Cited by 852
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J., Reynolds, B. A., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002035 · Cited by 736
Kennedy, D. O., & Wightman, E. L. (2011) · Advances in Nutrition · doi:10.3945/an.110.000117 · Cited by 684
Ramassamy, C. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.025 · Cited by 682
Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J. E., Janle, E. M., Lobo, J., Ferruzzi, M. G., Davies, P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.060061 · Cited by 645
Self-citationResveratrol bioavailability and toxicity in humans
Cottart, C., Nivet‐Antoine, V., Laguillier‐Morizot, C., & Beaudeux, J. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900437 · Cited by 592
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Small molecule SIRT1 activators for the treatment of aging and age-related diseases
Hubbard, B. P., & Sinclair, D. A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.004 · Cited by 569
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Resveratrol (RV): A pharmacological review and call for further research
Zhang, L.-X., Li, C.-X., Kakar, M. U., Khan, M. S., Wu, P.-F., Amir, R. M., Dai, D.-F., Naveed, M., Li, Q.-Y., Saeed, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112164 · Cited by 546
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Neuroprotective potential of phytochemicals
Kumar, G., & Khanum, F. (2012) · Pharmacognosy Reviews · doi:10.4103/0973-7847.99898 · Cited by 511
Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H.-L., Beal, M. F., & Gibson, G. E. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.10.008 · Cited by 485
Rezai-Zadeh, K., Arendash, G. W., Hou, H., Fernandez, F., Jensen, M., Runfeldt, M., Shytle, R. D., & Tan, J. (2008) · Brain Research · doi:10.1016/j.brainres.2008.02.107 · Cited by 459
Resveratrol: French Paradox Revisited
Catalgol, B., Batirel, S., Taga, Y., & Ozer, N. K. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00141 · Cited by 449
“It has no effect on the Aβ-producing enzymes β- and γ-secretases, but promote instead intracellular degradation of Aβ via a mechanism that involves the proteasome which may be induced by oxidative stress (Marambaud et al., 2005).”
BackgroundResveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F., García-Conesa, M., & Espín, J. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990407 · Cited by 449
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Saiko, P., Szakmary, A., Jaeger, W., & Szekeres, T. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2007.08.004 · Cited by 442
Singh, M., Arseneault, M., Sanderson, T., Murthy, V., & Ramassamy, C. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0735073 · Cited by 439
Capiralla, H., Vingtdeux, V., Zhao, H., Sankowski, R., Al‐Abed, Y., Davies, P., & Marambaud, P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07594.x · Cited by 426
Self-citationSirtuins — novel therapeutic targets to treat age-associated diseases
Lavu, S., Boss, O., Elliott, P. J., & Lambert, P. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2665 · Cited by 426
Neuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1
Gomes, B. A. Q., Silva, J. P. B., Romeiro, C. F. R., dos Santos, S. M., Rodrigues, C. A., Gonçalves, P. R., Sakai, J. T., Mendes, P. F. S., Varela, E. L. P., & Monteiro, M. C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8152373 · Cited by 403
Neuroprotective action of resveratrol
Bastianetto, S., Ménard, C., & Quirion, R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.09.011 · Cited by 407
Resveratrol: Its Biologic Targets and Functional Activity
Pervaiz, S., & Holme, A. L. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2412 · Cited by 405
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Biological Activities of Stilbenoids
Akinwumi, B., Bordun, K.-A., & Anderson, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030792 · Cited by 373
Protein homeostasis and aging in neurodegeneration
Douglas, P. M., & Dillin, A. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201005144 · Cited by 372
Review on Alzheimer’s Disease: Inhibition of Amyloid Beta and Tau Tangle Formation
Ashrafian, H., Zadeh, E. H., & Khan, R. H. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.192 · Cited by 368
Wang, J., Ho, L., Zhao, W., Ono, K., Rosensweig, C., Chen, L., Humala, N., Teplow, D. B., & Pasinetti, G. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0364-08.2008 · Cited by 361
Hartman, R. E., Shah, A., Fagan, A. M., Schwetye, K. E., Parsadanian, M., Schulman, R. N., Finn, M. B., & Holtzman, D. M. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.006 · Cited by 357
Naturally occurring phytochemicals for the prevention of Alzheimer’s disease
Kim, J., Lee, H. J., & Lee, K. W. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06562.x · Cited by 352
Jeon, B. T., Jeong, E. A., Shin, H. J., Lee, Y., Lee, D. H., Kim, H. J., Kang, S. S., Cho, G. J., Choi, W. S., & Roh, G. S. (2012) · Diabetes · doi:10.2337/db11-1498 · Cited by 351
Loureiro, J., Andrade, S., Duarte, A., Neves, A., Queiroz, J., Nunes, C., Sevin, E., Fenart, L., Gosselet, F., Coelho, M., et al. (2017) · Molecules · doi:10.3390/molecules22020277 · Cited by 341
Resveratrol—A boon for treating Alzheimer's disease?
Anekonda, T. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.04.004 · Cited by 339
Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases
Sun, A. Y., Wang, Q., Simonyi, A., & Sun, G. Y. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8111-y · Cited by 329
Inflammaging as a prodrome to Alzheimer's disease
Giunta, B., Fernandez, F., Nikolic, W. V., Obregon, D., Rrapo, E., Town, T., & Tan, J. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-51 · Cited by 327
Li, Q., Yang, H., Chen, Y., & Sun, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.062 · Cited by 322
A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Aβ Levels, and Alzheimer's Disease Risk
Dreses-Werringloer, U., Lambert, J.-C., Vingtdeux, V., Zhao, H., Vais, H., Siebert, A., Jain, A., Koppel, J., Rovelet-Lecrux, A., Hannequin, D., et al. (2008) · Cell · doi:10.1016/j.cell.2008.05.048 · Cited by 318
Self-citationHeat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases
Neef, D. W., Jaeger, A. M., & Thiele, D. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3453 · Cited by 307
Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy?
Weiskirchen, S., & Weiskirchen, R. (2016) · Advances in Nutrition · doi:10.3945/an.115.011627 · Cited by 306
Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302
Wang, J., Ho, L., Zhao, Z., Seror, I., Humala, N., Dickstein, D. L., Thiyagarajan, M., Percival, S. S., Talcott, S. T., & Maria Pasinetti, G. (2006) · The FASEB Journal · doi:10.1096/fj.06-6281com · Cited by 298
Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation
Feng, Y., Wang, X.-P., Yang, S.-G., Wang, Y.-J., Zhang, X., Du, X.-T., Sun, X.-X., Zhao, M., Huang, L., & Liu, R.-T. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.08.013 · Cited by 295
Reinisalo, M., Kårlund, A., Koskela, A., Kaarniranta, K., & Karjalainen, R. O. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/340520 · Cited by 284
Khan, M. M., Ahmad, A., Ishrat, T., Khan, M. B., Hoda, M. N., Khuwaja, G., Raza, S. S., Khan, A., Javed, H., Vaibhav, K., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.02.031 · Cited by 279
Resveratrol for Alzheimer's disease
Sawda, C., Moussa, C., & Turner, R. S. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13431 · Cited by 276
Lifespan and healthspan extension by resveratrol
Bhullar, K. S., & Hubbard, B. P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.012 · Cited by 274
Natural polyphenols against neurodegenerative disorders: Potentials and pitfalls
Ebrahimi, A., & Schluesener, H. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.01.006 · Cited by 270
Calabrese, V., Cornelius, C., Mancuso, C., Pennisi, G., Calafato, S., Bellia, F., Bates, T. E., Giuffrida Stella, A. M., Schapira, T., Dinkova Kostova, A. T., et al. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9775-9 · Cited by 268
Baxter, R. A. (2008) · Journal of Cosmetic Dermatology · doi:10.1111/j.1473-2165.2008.00354.x · Cited by 263
Curcumin inhibits aggregation of α-synuclein
Pandey, N., Strider, J., Nolan, W. C., Yan, S. X., & Galvin, J. E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0332-4 · Cited by 263
Dose-Dependency of Resveratrol in Providing Health Benefits
Mukherjee, S., Dudley, J. I., & Das, D. K. (2010) · Dose-Response · doi:10.2203/dose-response.09-015.mukherjee · Cited by 263
Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8
Porquet, D., Casadesús, G., Bayod, S., Vicente, A., Canudas, A. M., Vilaplana, J., Pelegrí, C., Sanfeliu, C., Camins, A., Pallàs, M., et al. (2013) · AGE · doi:10.1007/s11357-012-9489-4 · Cited by 262
Albani, D., Polito, L., Batelli, S., De Mauro, S., Fracasso, C., Martelli, G., Colombo, L., Manzoni, C., Salmona, M., Caccia, S., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06228.x · Cited by 260
Resveratrol: review on therapeutic potential and recent advances in drug delivery
Pangeni, R., Sahni, J. K., Ali, J., Sharma, S., & Baboota, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.919253 · Cited by 255
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Candelario-Jalil, E., de Oliveira, A. C. P., Gräf, S., Bhatia, H. S., Hüll, M., Muñoz, E., & Fiebich, B. L. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-25 · Cited by 223
“In addition, it has been recently demonstrated that resveratrol promotes intracellular degradation of amyloid β peptide via a mechanism that involves the proteasome [22].”
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Griñán-Ferré, C., Bellver-Sanchis, A., Izquierdo, V., Corpas, R., Roig-Soriano, J., Chillón, M., Andres-Lacueva, C., Somogyvári, M., Sőti, C., Sanfeliu, C., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101271 · Cited by 208
Antioxidant Effects of Resveratrol in Cardiovascular, Cerebral and Metabolic Diseases
Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M., Maciag, A., Puca, A. A., & Vecchione, C. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.021 · Cited by 203
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
“Also, an in vitro experiment showed that RES reduced the Aβ secretion and Aβ fibrils accumulation (Marambaud et al., 2005).”
BackgroundA Review of Dietary Phytochemicals and Their Relation to Oxidative Stress and Human Diseases
Guan, R., Van Le, Q., Yang, H., Zhang, D., Gu, H., Yang, Y., Sonne, C., Lam, S. S., Zhong, J., Jianguang, Z., et al. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2020.129499 · Cited by 169
Medeiros, R., Kitazawa, M., Passos, G. F., Baglietto-Vargas, D., Cheng, D., Cribbs, D. H., & LaFerla, F. M. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.051 · Cited by 163
Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8401-2 · Cited by 165
“Taking into account our results, a concern about the efficacy of resveratrol as an anti-Aβ drug remains to be determined; however, some studies have shown that resveratrol may binding to different assemblies of Aβ [75] and selectively remodels soluble oligomers and fibrils of Aβ [76], reduces plaque pathology in trans…”
ResultRodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Viewpoint: Mechanisms of Action and Therapeutic Potential of Neurohormetic Phytochemicals
Mattson, M. P., Son, T. G., & Camandola, S. (2007) · Dose-Response · doi:10.2203/dose-response.07-004.mattson · Cited by 137
“In models relevant to Alzheimer’s disease, resveratrol protected neuronal cells from being killed by amyloid β-peptide (Jang and Surh, 2003) and promoted the clearance of amyloid β-peptide from cultured cells (Marambaud et al., 2005).”
Divino da Rocha, M., Pereira Dias Viegas, F., Cristina Campos, H., Carolina Nicastro, P., Calve Fossaluzza, P., Alberto Manssour Fraga, C., J. Barreiro, E., & Viegas, C. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794480429 · Cited by 126
Xue, X., Wang, L.-R., Sato, Y., Jiang, Y., Berg, M., Yang, D.-S., Nixon, R. A., & Liang, X.-J. (2014) · Nano Letters · doi:10.1021/nl501839q · Cited by 125
Caloric restriction: Beneficial effects on brain aging and Alzheimer’s disease
Van Cauwenberghe, C., Vandendriessche, C., Libert, C., & Vandenbroucke, R. E. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9647-6 · Cited by 121
“…load Karuppagounder et al. 2009, Porquet et al. 2014 Lower Ab levels Halagappa et al. 2007, Hu et al. 2015, Porquet et al. 2013 Zhao et al. 2015 Marambaud et al. 2005 Conversion to non-toxic Ab Ladiwala et al. 2010 Reduced tau pathology Halagappa et al. 2007, Porquet et al. 2014 Reduced…”
BackgroundMetabolic effects of resveratrol: Addressing the controversies
Bitterman, J. L., & Chung, J. H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1808-8 · Cited by 109
“mer’s disease, resveratrol can reduce the accumulation of amyloid b (Ab) peptides in various cell line models [175], and the accumulation of Ab plaques [176].”
The Proteasome and Oxidative Stress in Alzheimer's Disease
Bonet-Costa, V., Pomatto, L. C.-D., & Davies, K. J. A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6802 · Cited by 99
Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Yang, Y., & Zhang, L. (2020) · Food & Function · doi:10.1039/c9fo02611h · Cited by 57
Yu, H., Yamashita, T., Hu, X., Bian, Z., Hu, X., Feng, T., Tadokoro, K., Morihara, R., & Abe, K. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120356 · Cited by 37
RetractedBiological and Computational Evaluation of Resveratrol Inhibitors against Alzheimer's Disease
Koukoulitsa, C., Villalonga-Barber, C., Csonka, R., Alexi, X., Leonis, G., Dellis, D., Hamelink, E., Belda, O., Steele, B. R., Micha-Screttas, M., et al. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2014.1003928 · Cited by 37
Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants
Zhao, H., Dreses-Werringloer, U., Davies, P., & Marambaud, P. (2008) · BMC Research Notes · doi:10.1186/1756-0500-1-38 · Cited by 31
“APP full-length (APP) and C-terminal fragments (C99 and C83) were analyzed by western blotting (WB) as described before [16], using antibodies directed against APP N-terminal domain (22C11, Chemicon) and APP C-terminal domain (R1, provided by Dr.”
MethodSelf-citationResveratrol promotes degradation of the human bile acid transporter ASBT (SLC10A2)
Chothe, P. P., & Swaan, P. W. (2014) · Biochemical Journal · doi:10.1042/bj20131428 · Cited by 29
Su, R., Han, Z.-Y., Fan, J.-P., & Zhang, Y.-L. (2010) · Neuroscience Bulletin · doi:10.1007/s12264-010-0131-0 · Cited by 27
Yin, W., Cerda-Hernández, N., Castillo-Morales, A., Ruiz-Tejada-Segura, M. L., Monzón-Sandoval, J., Moreno-Castilla, P., Pérez-Ortega, R., Bermudez-Rattoni, F., Urrutia, A. O., & Gutiérrez, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.602642 · Cited by 5
Metadata
- Authors
- Marambaud, P., Zhao, H., & Davies, P.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-11
- Volume
- 280
- Issue
- 45
- Pages
- 37377-37382
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2070815033
- Cited by
- 749
- References
- 31
- FWCI
- 15.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.